Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III AbbVie has reported the results of Phase II trials indicating that adults experiencing moderate to severe hidradenitis suppurativa, and who had previously not respon...
Find MoreRoche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...
Find MoreFlagship Pioneering has launched Omega Therapeutics with an aim to take forward the genomic medicine. The launch of Omega therapeutics was planned to focus on epigenetic drugs to target diseases. Study of changes in gene expressions without any changes in the DNA sequence is known as Epigenetics. This oft...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.